Abstract:All-trans-retinoic acid (ATRA), the biologically most active metabolite of vitamin A, plays a major role in the regulation of cellular differentiation and proliferation, and it is also an important pharmacological agent particularly used in the treatment of cancer, skin, neurodegenerative and autoimmune diseases. However, ATRA is very easy to be metabolized into 4-hydroxyl-RA in vivo by CYP26A1, an inducible cytochrome P450 enzyme, eventually into more polar metabolites. Therefore, it is vital to develop specific retinoic acid metabolism blocking agents (RAMBAs) to inhibit the metabolic enzyme CYP26A1 in the treatment of relevant diseases aforementioned.In this study, CYP26A1 and its interactions with retinoic acid-competitive metabolism blocking agents were investigated by a combined ligand- and structure-based approach. First, since the crystal structure of CYP26A1 protein has not been determined, we constructed the 3D structure of CYP26A1 using homology modeling. In order to achieve a deeper insight into the mode of action of RAMBAs in the active site, the molecular superimposition model and the common feature pharmacophore model were constructed, and molecular docking was performed. The molecular superimposition model is composed of three features: the main chain groups, side chain groups, and azole groups. The common feature pharmacophore model consists of five chemical features: four hydrophobic groups and one hydrogen acceptor (HHHHA). The results of molecular docking show that the characteristic groups of RAMBAs were mapped into three different active pockets, respectively.A structure-activity relationship (SAR) was obtained by a combination of the molecular superimposition and docking results with the pharmacophore model. This study gives more insight into the interaction model inside the CYP26A1 active site and provides guidance for the design of more potent and possibly more selective RAMBAs. (C) 2014 Elsevier Inc. All rights reserved.

Development and therapeutic potential of allosteric retinoic acid receptor-related orphan receptor ?t (ROR?t) inverse agonists for autoimmune diseases

The Pathophysiological Roles and Regulatory Mechanism of Retinoic Acid Receptor-related Orphan Receptors

Retinoic acid receptor-related orphan receptor gamma-t (RORγt) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present).

Discovery and Structural Optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1h)-ones As RORc Inverse Agonists

Small molecule inhibitors of RORγt for Th17 regulation in inflammatory and autoimmune diseases

Modes of Action Insights from the Crystallographic Structures of Retinoic Acid Receptor-Related Orphan Receptor-Γt (Rorγt)

The evolution paths of some reprehensive scaffolds of RORt modulators, a perspective from medicinal chemistry

Small molecules targeting RORγt inhibit autoimmune disease by suppressing Th17 cell differentiation

Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.

Molecular Recognition of CYP26A1 Binding Pockets and Structure–activity Relationship Studies for Design of Potent and Selective Retinoic Acid Metabolism Blocking Agents

ROR Nuclear Receptors: Structures, Related Diseases, and Drug Discovery

Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists

Molecular Mechanism of Action of RORγt Agonists and Inverse Agonists: Insights from Molecular Dynamics Simulation

Molecular Dynamics Simulations on RORγt: Insights into Its Functional Agonism and Inverse Agonism

Discovery of Novel N-sulfonamide-tetrahydroisoquinolines As Potent Retinoic Acid Receptor-Related Orphan Receptor Γt Agonists

Investigations of Retinoic Acid Receptor-Related Orphan Receptor-Gamma T (rorγt) Agonists: a Combination of 3D-QSAR, Molecular Docking and Molecular Dynamics

Targeting Th17 Cells with Small Molecules and Small Interference RNA

Retinoic Acid Receptor-Related Orphan Receptor Γt (rorγt) Agonists As Potential Small Molecule Therapeutics for Cancer Immunotherapy.

Agonist Lock Touched and Untouched Retinoic Acid Receptor-Related Orphan Receptor-γt (rorγt) Inverse Agonists: Classification Based on the Molecular Mechanisms of Action.

Discovery of <i>tert</i>-amine-based RORt agonists

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.